Daniel Erlanson
Chief Innovation Officer at Frontier Medicines | San Francisco, California, United States
Daniel Erlanson’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Chief Innovation Officer at Frontier Medicines in January 2024 - Present
Senior VP of Innovation and Discovery at Frontier Medicines in January 2022 - January 2024
VP of Chemistry at Frontier Medicines in January 2019 - January 2022
Co-founder, Board Member, and VP of Chemistry at Carmot Therapeutics, Inc. in January 2008 - January 2019
Associate Director of Medicinal Chemistry at Sunesis Pharmaceuticals in January 2007 - January 2008
Senior Scientist at Sunesis Pharmaceuticals in January 2003 - January 2007
Staff Scientist at Sunesis Pharmaceuticals in January 2001 - January 2003
Scientist at Sunesis Pharmaceuticals in January 1999 - January 2001
NIH Postdoctoral Fellow at Sunesis Pharmaceuticals in January 1998 - January 1999
Postdoctoral Fellow at Genentech in January 1997 - January 1998
Carmot has been acquired by Roche in early 2024, making the company a member of the Roche Group. Carmot Therapeutics is a clinical-stage biotechnology company that is focused on advancing life-changing therapeutics for people with obesity and diabetes. We are utilizing Chemotype Evolution, a pioneering drug discovery platform, to identify novel incretin receptor signaling targets to develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. We have three clinical candidates: CT-388, CT-868 and CT-996.
Discover more about Frontier Medicines
Senior Vice President and Global Head of Cardiovascular, Renal and Metabolism Product Development, Roche-Genentech
Clinical Asst. Professor of Medicine at Rutgers New Jersey Medical School
(July 2009 – Present)
VP, Program Leadership
VP, Program Leadership at Mirum Pharmaceuticals, Inc.
(June 2024 – Present)
C-Suite Executive Assistant, Strategic Partner to Leadership
Executive Assistant at Carmot Therapeutics, Inc.
(Jan 2023 – Present)
Clinical Research Professional
Senior Clinical Trial Manager at Carmot Therapeutics, Inc.
(Jul 2023 – Present)
Global Regulatory Affairs (Clinical/Nonclinical)
Carmot Therapeutics, a member of the Roche Group
Senior Director, Regulatory Affairs; Head of Regulatory Affairs. GIP/GLP-1 receptor agonists, indicated for chronic weight management therapy of patients who are overweight or with obesity, with or without comorbidities. Type...
Scientist II at Carmot Therapeutics
Scientist II at Carmot Therapeutics, Inc.
(May 2016 – Present)
What is Daniel Erlanson email address?
Email Daniel Erlanson at [email protected]. This email is the most updated Daniel Erlanson's email found in 2026.
How to contact Daniel Erlanson?
To contact Daniel Erlanson send an email to [email protected]. (updated on July 2026)
What company does Daniel Erlanson work for?
Daniel Erlanson works for Frontier Medicines.
What is Daniel Erlanson's role at Frontier Medicines?
Daniel Erlanson is Chief Innovation Officer
What industry does Daniel Erlanson work in?
Daniel Erlanson works in the Biotechnology industry.
